Khadijeh Ahmadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Khadijeh Ahmadi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Sobhan Faezi
Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
2 shared publicationsAli Atash Abparvar
Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publication- Angela Stufano
Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
1 shared publication Ebrahim Eftekhar
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publicationGholamreza Pouladfar
Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication- Hamid Reza Jahantigh
Department of Pathology, Faculty of Medicine, Emory University, Atlanta, GA, USA
1 shared publication
Latest Publications
- Open Access
The Candidate Antigens to Achieving an Effective Vaccine against Staphylococcus aureus
Staphylococcus aureus (S. aureus) is an opportunistic pathogen that causes various inflammatory local infections, from those of the skin to postinfectious glomerulonephritis. These infections could result in serious threats, putting the life of the patient in danger. Antibiotic-resistant S. aureus could lead to dramatic increases in human mortality. Antibiotic resistance would explicate the failure of current antibiotic therapies. So, it is obvious that an effective vaccine against S. aureus infections would significantly reduce costs related to care in hospitals. Bacterial vaccines have important impacts on morbidity and mortality caused by several common pathogens, however, a prophylactic vaccine against staphylococci has not yet been produced. During the last decades, the efforts to develop an S. aureus vaccine have faced two major failures in clinical trials. New strategies for vaccine development against S. aureus has supported the use of multiple antigens, the inclusion of adjuvants, and the focus on various virulence mechanisms. We aimed to present a compressive review of different antigens of S. aureus and also to introduce vaccine candidates undergoing clinical trials, from which can help us to choose a suitable and effective candidate for vaccine development against S. aureus.
Open AccessThe Candidate Antigens to Achieving an Effective Vaccine against Staphylococcus aureus
Staphylococcus aureus (S. aureus) is an opportunistic pathogen that causes various inflammatory local infections, from those of the skin to postinfectious glomerulonephritis. These infections could result in serious threats, putting the life of the patient in danger. Antibiotic-resistant S. aureus could lead to dramatic increases in human mortality. Antibiotic resistance would explicate the failure of current antibiotic therapies. So, it is obvious that an effective vaccine against S. aureus infections would significantly reduce costs related to care in hospitals. Bacterial vaccines have important impacts on morbidity and mortality caused by several common pathogens, however, a prophylactic vaccine against staphylococci has not yet been produced. During the last decades, the efforts to develop an S. aureus vaccine have faced two major failures in clinical trials. New strategies for vaccine development against S. aureus has supported the use of multiple antigens, the inclusion of adjuvants, and the focus on various virulence mechanisms. We aimed to present a compressive review of different antigens of S. aureus and also to introduce vaccine candidates undergoing clinical trials, from which can help us to choose a suitable and effective candidate for vaccine development against S. aureus.
- 1 July 2021
- Published by Elsevier in Journal of Immunological Methods
- Vol. 494, 113055
Protective efficacy of Hla-MntC-SACOL0723 fusion protein adjuvanted in alum and MPL against Staphylococcus aureus sepsis infection in mice
- 1 July 2021
- Published by Elsevier in Journal of Immunological Methods
- Vol. 494, 113055
Protective efficacy of Hla-MntC-SACOL0723 fusion protein adjuvanted in alum and MPL against Staphylococcus aureus sepsis infection in mice